ARGX
Brief description of study
A Phase 3, Randomized, Double-Masked, Placebo-Controlled investigating the safety and effects of weekly subcutaneous injections of Efgartigimod PH20 in adults with active, moderate-to-severe TED. The study aims to evaluate the percentage of participants who are proptosis responders at week 24.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
